Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study

Author:

Li Haorui1,Guo Yu1,Sun Xugang1,Lu Yang1,Chang Shaofei2,Wang Xiuchao1,Gao Song1,Ma Weidong1,Wang Jian1,Gao Chuntao1,Zhao Tiansuo1

Affiliation:

1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer

2. Shanxi provincial people's hospital

Abstract

Abstract Purpose The survival advantages of adjuvant AG (nab-paclitaxel plus gemcitabine) or S-1 chemotherapy compared with GEM (gemcitabine) chemotherapy for resectable pancreatic cancer have been confirmed by the APACT study in 2019 and the JASPAC01 trial in 2016 respectively. However, the evidence about the effectiveness of AG or S-1 in real-world clinical practice is not sufficient. Methods Our study included 246 pancreatic cancer patients who underwent surgical treatment and received postoperative adjuvant chemotherapy with AG, S-1, or GEM scheme at Tianjin Medical University Cancer Institute and Hospital from June 2015 to July 2021. The primary outcome was overall survival (OS) and recurrence-free survival (RFS). In general, 246 patients were included, of whom 54(22%) received adjuvant AG, 103(41%) received adjuvant S-1, and 89(37%) received adjuvant GEM. Results Adjuvant S-1 was related to a prolonged OS compared to GEM (median OS S-1 vs GEM: 27.0 vs 20.0 months; HR: 0.65, P = .016) and a significantly prolonged RFS compared to GEM (median RFS S-1 vs GEM: 20.0 vs 8.2 months; HR: 0.58, P = .002). After adjusting for known prognostic factors in multivariate Cox regression analysis, this survival benefit persists and is consistent in most subgroups in our subgroup analysis. However, no statistically significant differences in OS or RFS were seen between the patients treated with AG and patients treated with GEM. Conclusion To conclude, this real-world study demonstrated that S-1 chemotherapy is associated with superior survival compared to GEM chemotherapy, while the survival advantage of AG chemotherapy compared to GEM chemotherapy remains to be further studied.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3